Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have emerged as effective treatments for obesity, achieving 15–25% weight loss while improving glycemic control, cardiovascular outcomes, and hepatic metabolism [5]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.